Key Highlights
- Sun Pharmaceutical Industries has put forward a $13 billion all-cash acquisition proposal for Organon (OGN)
- If successful, this transaction would represent Sun Pharma’s biggest acquisition in its history, backed by financing from JP Morgan, MUFG, and Citi
- OGN shares surged approximately 25% during Friday’s trading session, building on a 20% year-to-date increase
- Competing acquisition proposals have also been submitted by Grünenthal and EQT for the pharmaceutical company
- Sun Pharma’s initial $12 billion proposal came earlier this month; the current bid represents a significant increase
Shares of Organon (OGN) experienced a dramatic surge exceeding 25% during Friday’s session following disclosure that India-based Sun Pharmaceutical Industries is pursuing a $13 billion all-cash acquisition of the women’s health-focused pharmaceutical company.
The Economic Times broke the story Thursday night, referencing sources with knowledge of the negotiations. OGN initially climbed approximately 8% in after-hours trading before continuing its rally throughout Friday’s regular session.
When the report initially surfaced, Organon carried a market capitalization of merely $2.2 billion. The proposed $13 billion purchase price would constitute an extraordinary premium relative to the stock’s recent trading levels.
Should the transaction close, it would establish a new record as Sun Pharma’s largest-ever acquisition. The complete all-cash proposal has secured full financing commitments from JP Morgan, MUFG, and Citi.
Sun Pharma’s strategy involves integrating Organon into its current business structure. The proposal does not involve issuing Sun Pharmaceutical equity to existing Organon shareholders.
This represents Sun Pharma’s second approach toward acquiring the company. Reports from earlier this month indicated the Indian pharmaceutical manufacturer had submitted a $12 billion proposal. The newly reported $13 billion offer constitutes a $1 billion escalation within just weeks.
Competitive Bidding Environment Emerges
Sun Pharma faces competition in its pursuit of Organon. Germany-based pharmaceutical company Grünenthal and Sweden’s private equity powerhouse EQT have both reportedly submitted competing acquisition proposals for the business.
The competitive interest underscores the attractiveness of Organon’s asset portfolio — an extensive collection of pharmaceutical products and therapies concentrated primarily in women’s healthcare, combined with its valuable U.S. manufacturing capabilities.
Organon became an independent entity through a spinoff from Merck in June 2021. The stock has faced challenges since separation, declining nearly 30% over the trailing 12-month period despite Friday’s substantial rally.
Extraordinary Trading Activity
The acquisition reports sparked intense trading activity. Approximately 5.2 million OGN shares traded hands shortly after Friday’s market opening — nearly equaling the complete three-month average daily volume of 5.9 million within just the initial trading hours.
Friday’s 25.47% rally elevated the stock’s year-to-date performance to a positive 20.25% return.
OGN traded above $9.20 per share during Thursday’s after-hours session, representing a significant premium from its relatively modest $2.2 billion market capitalization at Thursday’s closing bell.
Neither Sun Pharma nor Organon had issued official statements confirming any transaction as of Friday afternoon.
